For taking toll on vulture numbers, govt bans cattle drug vial

Image
Press Trust of India New Delhi
Last Updated : Sep 18 2015 | 2:57 PM IST
Alarmed by the "steep" decline in the vulture population in India and to protect the bird from "extinction", the government has banned the multidose vial of anti-inflammatory drug diclofenac, which is used for cattle.
The multidose variant of the drug, which is harmless when administered to cattle, is fatal for vultures, who routinely feed on the carcass of dead cattle.
Studies have shown that the drug causes kidney and liver failure in vultures, leading to their death.
The Union Environment Ministry said that the commonly-used anti-inflammatory cattle drug is considered to be the "chief" cause for the "steep" decline in the numbers of vultures in recent years.
"Keeping in view the severity of the situation and the need to conserve and protect vultures from extinction, the Environment Ministry has requested the Health Ministry to restrict the pack of diclofenac for human use in single dose only," an official statement said.
Earlier, the Environment Ministry, in consultation with Health Ministry, had published a Gazette notification on July 17 restricting the packaging of diclofenac exclusively to single dose for human use.
"Even after banning the use of diclofenac for veterinary use, the multi-dose vials available in the market for human use were widely misused for veterinary purpose. This in turn has had a severe impact on the population of vultures," the Environment Ministry said.
The government had in 2006 imposed a ban on the use of diclofenac for treating cattle. Conservationists have been advocating a ban on the drug since it was linked to a decline in the population of the birds in South Asia, including India, where the vulture population has come down drastically.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 18 2015 | 2:57 PM IST

Next Story